Letter | Published:

GlycoDelete engineering of mammalian cells simplifies N-glycosylation of recombinant proteins

Nature Biotechnology volume 32, pages 485489 (2014) | Download Citation

Abstract

Heterogeneity in the N-glycans on therapeutic proteins causes difficulties for protein purification and process reproducibility and can lead to variable therapeutic efficacy. This heterogeneity arises from the multistep process of mammalian complex-type N-glycan synthesis. Here we report a glycoengineering strategy—which we call GlycoDelete—that shortens the Golgi N-glycosylation pathway in mammalian cells. This shortening results in the expression of proteins with small, sialylated trisaccharide N-glycans and reduced complexity compared to native mammalian cell glycoproteins. GlycoDelete engineering does not interfere with the functioning of N-glycans in protein folding, and the physiology of cells modified by GlycoDelete is similar to that of wild-type cells. A therapeutic human IgG expressed in GlycoDelete cells had properties, such as reduced initial clearance, that might be beneficial when the therapeutic goal is antigen neutralization. This strategy for reducing N-glycan heterogeneity on mammalian proteins could lead to more consistent performance of therapeutic proteins and modulation of biopharmaceutical functions.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous β1, 4-N-acetylglucosaminyltransferase III and Golgi α-mannosidase II. Biotechnol. Bioeng. 93, 851–861 (2006).

  2. 2.

    et al. Control of rHuEPO biological activity: the role of carbohydrate. Exp. Hematol. 32, 1146–1155 (2004).

  3. 3.

    , , , & Engineering complex-type N-glycosylation in Pichia pastoris using GlycoSwitch technology. Nat. Protoc. 4, 58–70 (2008).

  4. 4.

    et al. Humanization of yeast to produce complex terminally sialylated glycoproteins. Science 313, 1441–1443 (2006).

  5. 5.

    et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol. Cancer Ther. 12, 2031–2042 (2013).

  6. 6.

    et al. Comparison of cell lines for stable production of fucose-negative antibodies with enhanced ADCC. Biotechnol. Bioeng. 94, 680–688 (2006).

  7. 7.

    , , & Structure and function in rhodopsin: high-level expression of rhodopsin with restricted and homogeneous N-glycosylation by a tetracycline-inducible N-acetylglucosaminyltransferase I-negative HEK293S stable mammalian cell line. Proc. Natl. Acad. Sci. USA 99, 13419–13424 (2002).

  8. 8.

    et al. Identification of a gene coding for a deglycosylating enzyme in Hypocrea jecorina. FEMS Microbiol. Lett. 303, 9–17 (2010).

  9. 9.

    , , & Complete cDNA sequence encoding human β-galactoside α-2,6-sialyltransferase. Nucleic Acids Res. 18, 667 (1990).

  10. 10.

    et al. Structural insights into the extracellular assembly of the hematopoietic Flt3 signaling complex. Blood 118, 60–68 (2011).

  11. 11.

    , & Intracellular signaling by the unfolded protein response. Annu. Rev. Cell Dev. Biol. 22, 487–508 (2006).

  12. 12.

    et al. Isolation of cDNA for a human granulocyte-macrophage colony-stimulating factor by functional expression in mammalian cells. Proc. Natl. Acad. Sci. USA 82, 4360–4364 (1985).

  13. 13.

    et al. N- and O-linked carbohydrates and glycosylation site occupancy in recombinant human granulocyte-macrophage colony-stimulating factor secreted by a Chinese hamster ovary cell line. Eur. J. Biochem. 271, 907–919 (2004).

  14. 14.

    et al. Inhibition of hybrid- and complex-type glycosylation reveals the presence of the GlcNAc transferase I-independent fucosylation pathway. Glycobiology 16, 748–756 (2006).

  15. 15.

    , , , & Thermofluor-based high-throughput stability optimization of proteins for structural studies. Anal. Biochem. 357, 289–298 (2006).

  16. 16.

    et al. Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J. Cell. Physiol. 140, 323–334 (1989).

  17. 17.

    et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity. Blood 115, 4393–4402 (2010).

  18. 18.

    et al. Glycan variability on a recombinant IgG antibody transiently produced in HEK-293E cells. N. Biotechnol. 29, 471–476 (2012).

  19. 19.

    Glycosylation as a strategy to improve antibody-based therapeutics. Nat. Rev. Drug Discov. 8, 226–234 (2009).

  20. 20.

    & FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 7, 715–725 (2007).

  21. 21.

    , , & Impact of immune complex size and glycosylation on IgG binding to human FcγRs. J. Immunol. 190, 4315–4323 (2013).

  22. 22.

    & Primary structure and functional characterization of a human 5–HT1D-type serotonin receptor. Mol. Pharmacol. 40, 143–148 (1991).

  23. 23.

    , , & Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti–aquaporin-4 immunoglobulin G into therapeutic antibody. Ann. Neurol. 73, 77–85 (2013).

  24. 24.

    et al. Dominant suppression of inflammation by glycan-hydrolyzed IgG. Proc. Natl. Acad. Sci. USA 110, 10252–10257 (2013).

  25. 25.

    & Sugar-free antibodies—the bacterial solution to autoimmunity? Ann. NY Acad. Sci. 1173, 664–669 (2009).

  26. 26.

    Anonymous. Biosimilar, biobetter and next generation therapeutic antibodies. MAbs 3, 107–110 (2011).

  27. 27.

    et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 26, 966–968 (2010).

  28. 28.

    , , , & An improved colorimetric assay for interleukin 2. J. Immunol. Methods 93, 157–165 (1986).

  29. 29.

    et al. Structural basis for Fc γRIIa recognition of human IgG and formation of inflammatory signaling complexes. J. Immunol. 187, 3208–3217 (2011).

  30. 30.

    et al. Robust recombinant FcRn production in mammalian cells enabling oriented immobilization for IgG binding studies. J. Immunol. Methods 375, 20–29 (2012).

Download references

Acknowledgements

We thank G. Pontini, Y. Poitevin, L. Bernasconi, D. Schrag and S. Raimondi (NovImmune) for their help with anti-CD20 generation and characterization; S. Savvides (Ghent University) for providing the 293SGnTI(−) clone expressing the Flt3 receptor extracellular domain; E. Van Damme (Ghent University) for providing ConA; and E. Dirksen and K. Nooijen (Merck) for the LC-MS analysis of anti-CD20. L.M. and M.B. are supported by predoctoral fellowships, and N.F. by a postdoctoral fellowship, of the Fund for Scientific Research-Flanders (FWO). F.S. and S.D. are supported by predoctoral fellowships of agentschap voor Innovatie door Wetenschap en Technologie (IWT) Flanders (Strategic Basic Research fellowship nos. 101456 and 111252). This research was supported by VIB, Ghent University Industrial Research Fund (UGent-IOF) Advanced Grant no. 041 (N.C.), FWO research project grant no. G.0.541.08.N.10 (N.C.) and Hercules Foundation grant no. AUGE019 (B.D.).

Author information

Author notes

    • Leander Meuris
    • , Francis Santens
    •  & Greg Elson

    These authors contributed equally to this work.

Affiliations

  1. Unit for Medical Biotechnology, Inflammation Research Center (IRC), VIB, Ghent, Belgium.

    • Leander Meuris
    • , Francis Santens
    • , Nele Festjens
    • , Morgane Boone
    • , Evelyn Plets
    • , Erica Houthuys
    •  & Nico Callewaert
  2. Laboratory for Protein Biochemistry and Biomolecular Engineering, Department of Biochemistry and Microbiology, Ghent University, Ghent, Belgium.

    • Leander Meuris
    • , Francis Santens
    • , Nele Festjens
    • , Morgane Boone
    • , Simon Devos
    • , Evelyn Plets
    • , Erica Houthuys
    • , Bart Devreese
    •  & Nico Callewaert
  3. NovImmune SA, Plan-Les-Ouates, Geneva, Switzerland.

    • Greg Elson
    • , Anaëlle Dos Santos
    • , François Rousseau
    • , Pauline Malinge
    • , Giovanni Magistrelli
    • , Laura Cons
    •  & Laurence Chatel

Authors

  1. Search for Leander Meuris in:

  2. Search for Francis Santens in:

  3. Search for Greg Elson in:

  4. Search for Nele Festjens in:

  5. Search for Morgane Boone in:

  6. Search for Anaëlle Dos Santos in:

  7. Search for Simon Devos in:

  8. Search for François Rousseau in:

  9. Search for Evelyn Plets in:

  10. Search for Erica Houthuys in:

  11. Search for Pauline Malinge in:

  12. Search for Giovanni Magistrelli in:

  13. Search for Laura Cons in:

  14. Search for Laurence Chatel in:

  15. Search for Bart Devreese in:

  16. Search for Nico Callewaert in:

Contributions

L.M.: took the GlycoDelete technology from concept to reality: cell engineering, cell characterization, GM-CSF analytics, and thermofluor assays and co-wrote the manuscript. F.S.: made key contributions in the full exploration of the GlycoDelete technology: GM-CSF analytics, anti-CD20 analytics, and pharmacokinetics experiment, and co-wrote the manuscript. G.E.: made key contributions to the exploration of GlycoDelete technology for modulating antibody properties: experimental design, and supervision and interpretation of anti-CD20 bioanalytics experiments, and manuscript correction. N.F.: bioactivity, immunogenicity ELISA and pharmacokinetics experiments, contributed to the manuscript. M.B.: gene expression experiments and data processing. A.D.S.: ADCC, ELISA FcγR binding and CD20-binding assays. S.D.: LC-MS/MS experiments and analysis. F.R.: anti-CD20 expression construct. (This plasmid is not explicitly mentioned in the text and is an unpublished resource that was made available to us through the work of F.R.) E.P.: assisted with immunogenicity ELISA experiments. E.H.: pharmacokinetics experiment. P.M. and G.M.: SPR and BLI experiments. L. Cons and L. Chatel: pharmacokinetics experiment. B.D.: supervision of LC-MS/MS experiments. N.C.: conceived the GlycoDelete technology, initiated the project, assisted in experimental design and interpretation, and co-wrote the manuscript.

Competing interests

L.M. and N.C. are inventors on patent applications covering the GlycoDelete technology (WO/2010/015722).

Corresponding author

Correspondence to Nico Callewaert.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Figures 1–15, Supplementary Tables 1–8 and Supplementary Notes 1–6

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nbt.2885

Further reading